Ceribell, Inc. is a commercial-stage medical technology company, which engages in the provision of transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy | $19 |
| Jun-24-25 | Initiated | BTIG Research | Buy | $30 |
| Apr-04-25 | Initiated | Ladenburg Thalmann | Buy | $32 |
| Nov-05-24 | Initiated | William Blair | Outperform | |
| Nov-05-24 | Initiated | TD Cowen | Buy | $31 |
| Nov-05-24 | Initiated | JP Morgan | Overweight | $32 |
| Nov-05-24 | Initiated | Canaccord Genuity | Buy | $30 |
| Nov-05-24 | Initiated | BofA Securities | Buy | $32 |